![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA ISSUES DRAFT GUIDANCE ON BIORESEARCH MONITORING PMA APPLICATIONS
FDA ISSUES DRAFT GUIDANCE ON BIORESEARCH MONITORING PMA APPLICATIONS
June 19, 2006
The FDA has published draft guidance for the review and inspection of premarket approval (PMA) applications under its bioresearch monitoring (BIMO) program.
The guidance addresses the process for BIMO review of clinical and nonclinical information in PMA applications and related inspections, the agency said. Premarket notification, or 510(k), submissions are not addressed in the guidance, the agency noted.
The document, "Draft Guidance for Industry and Food and Drug Administration Staff; the Review and Inspection of Premarket Approval Applications Under the Bioresearch Monitoring Program," can be viewed at http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0228-gdl0001.pdf (http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0228-gdl0001.pdf).
Comments are due by September 18.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct